Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 16/20 | 0.65 |
| ▸ | CCNK | O75909 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242721 | 0.87 | CDK9 (0.49) | CDK9CCNKCCNT1HDAC3HDAC1 | |
| SCHEMBL10242899 | 0.85 | CDK9 (0.54) | CDK9CCNT1PIK3CA | |
| SCHEMBL10242883 | 0.85 | CDK9 (0.52) | CDK9CCNKCCNT1 | |
| SCHEMBL1946717 | 0.85 | CCNT1 (0.63) | CDK9CCNKCCNT1HDAC3HDAC1 | |
| SCHEMBL10285642 | 0.84 | CCNT1 (0.64) | CDK9CCNKCCNT1HDAC3HDAC1 | |
| SCHEMBL10242056 | 0.84 | CDK9 (0.55) | CDK9CCNT1PIK3CA | |
| SCHEMBL10242714 | 0.83 | CDK9 (0.50) | CDK9CCNKCCNT1 | |
| SCHEMBL10242075 | 0.83 | CDK9 (0.50) | CDK9CCNKCCNT1 | |
| SCHEMBL10241826 | 0.82 | CDK9 (0.62) | CDK9CCNT1PIK3CA | |
| SCHEMBL10242727 | 0.81 | CDK9 (0.62) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CDK9 6/4885CCNK 27/4885CCNT1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.